A citation-based method for searching scientific literature

Jonathan C Cohen, Jay D Horton, Helen H Hobbs. Science 2011
Times Cited: 1445







List of co-cited articles
553 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes.
Zobair M Younossi, Aaron B Koenig, Dinan Abdelatif, Yousef Fazel, Linda Henry, Mark Wymer. Hepatology 2016
23

Mechanisms of NAFLD development and therapeutic strategies.
Scott L Friedman, Brent A Neuschwander-Tetri, Mary Rinella, Arun J Sanyal. Nat Med 2018
13

Design and validation of a histological scoring system for nonalcoholic fatty liver disease.
David E Kleiner, Elizabeth M Brunt, Mark Van Natta, Cynthia Behling, Melissa J Contos, Oscar W Cummings, Linda D Ferrell, Yao-Chang Liu, Michael S Torbenson, Aynur Unalp-Arida,[...]. Hepatology 2005
12

The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases.
Naga Chalasani, Zobair Younossi, Joel E Lavine, Michael Charlton, Kenneth Cusi, Mary Rinella, Stephen A Harrison, Elizabeth M Brunt, Arun J Sanyal. Hepatology 2018
10

NAFLD: a multisystem disease.
Christopher D Byrne, Giovanni Targher. J Hepatol 2015
9

The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD).
Elena Buzzetti, Massimo Pinzani, Emmanuel A Tsochatzis. Metabolism 2016
9

Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease.
Stefano Romeo, Julia Kozlitina, Chao Xing, Alexander Pertsemlidis, David Cox, Len A Pennacchio, Eric Boerwinkle, Jonathan C Cohen, Helen H Hobbs. Nat Genet 2008
8



Nonalcoholic fatty liver disease.
Paul Angulo. N Engl J Med 2002
7

Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease.
Kerry L Donnelly, Coleman I Smith, Sarah J Schwarzenberg, Jose Jessurun, Mark D Boldt, Elizabeth J Parks. J Clin Invest 2005
7

Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention.
Zobair Younossi, Quentin M Anstee, Milena Marietti, Timothy Hardy, Linda Henry, Mohammed Eslam, Jacob George, Elisabetta Bugianesi. Nat Rev Gastroenterol Hepatol 2018
7



Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis.
Zobair Younossi, Frank Tacke, Marco Arrese, Barjesh Chander Sharma, Ibrahim Mostafa, Elisabetta Bugianesi, Vincent Wai-Sun Wong, Yusuf Yilmaz, Jacob George, Jiangao Fan,[...]. Hepatology 2019
698
6

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.
Arun J Sanyal, Naga Chalasani, Kris V Kowdley, Arthur McCullough, Anna Mae Diehl, Nathan M Bass, Brent A Neuschwander-Tetri, Joel E Lavine, James Tonascia, Aynur Unalp,[...]. N Engl J Med 2010
6

Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.
Matthew James Armstrong, Piers Gaunt, Guruprasad P Aithal, Darren Barton, Diana Hull, Richard Parker, Jonathan M Hazlehurst, Kathy Guo, George Abouda, Mark A Aldersley,[...]. Lancet 2016
944
6




Mitochondrial dysfunction precedes insulin resistance and hepatic steatosis and contributes to the natural history of non-alcoholic fatty liver disease in an obese rodent model.
R Scott Rector, John P Thyfault, Grace M Uptergrove, E Matthew Morris, Scott P Naples, Sarah J Borengasser, Catherine R Mikus, Matthew J Laye, M Harold Laughlin, Frank W Booth,[...]. J Hepatol 2010
320
5

Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up.
Mattias Ekstedt, Hannes Hagström, Patrik Nasr, Mats Fredrikson, Per Stål, Stergios Kechagias, Rolf Hultcrantz. Hepatology 2015
5

The natural history of nonalcoholic fatty liver disease: a population-based cohort study.
Leon A Adams, James F Lymp, Jenny St Sauver, Schuyler O Sanderson, Keith D Lindor, Ariel Feldstein, Paul Angulo. Gastroenterology 2005
5

Fructose and sugar: A major mediator of non-alcoholic fatty liver disease.
Thomas Jensen, Manal F Abdelmalek, Shelby Sullivan, Kristen J Nadeau, Melanie Green, Carlos Roncal, Takahiko Nakagawa, Masanari Kuwabara, Yuka Sato, Duk-Hee Kang,[...]. J Hepatol 2018
354
5

From NAFLD to NASH to cirrhosis-new insights into disease mechanisms.
Alexander Wree, Lori Broderick, Ali Canbay, Hal M Hoffman, Ariel E Feldstein. Nat Rev Gastroenterol Hepatol 2013
377
5


Molecular mechanisms of lipotoxicity and glucotoxicity in nonalcoholic fatty liver disease.
Manoela Mota, Bubu A Banini, Sophie C Cazanave, Arun J Sanyal. Metabolism 2016
244
5

Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States.
Robert J Wong, Maria Aguilar, Ramsey Cheung, Ryan B Perumpail, Stephen A Harrison, Zobair M Younossi, Aijaz Ahmed. Gastroenterology 2015
5

Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis.
Eduardo Vilar-Gomez, Yadina Martinez-Perez, Luis Calzadilla-Bertot, Ana Torres-Gonzalez, Bienvenido Gra-Oramas, Licet Gonzalez-Fabian, Scott L Friedman, Moises Diago, Manuel Romero-Gomez. Gastroenterology 2015
5

The global NAFLD epidemic.
Rohit Loomba, Arun J Sanyal. Nat Rev Gastroenterol Hepatol 2013
5

Cause, Pathogenesis, and Treatment of Nonalcoholic Steatohepatitis.
Anna M Diehl, Christopher Day. N Engl J Med 2017
558
5

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial.
Zobair M Younossi, Vlad Ratziu, Rohit Loomba, Mary Rinella, Quentin M Anstee, Zachary Goodman, Pierre Bedossa, Andreas Geier, Susanne Beckebaum, Philip N Newsome,[...]. Lancet 2019
488
5

Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies.
Siddharth Singh, Alina M Allen, Zhen Wang, Larry J Prokop, Mohammad H Murad, Rohit Loomba. Clin Gastroenterol Hepatol 2015
837
5


A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
Philip N Newsome, Kristine Buchholtz, Kenneth Cusi, Martin Linder, Takeshi Okanoue, Vlad Ratziu, Arun J Sanyal, Anne-Sophie Sejling, Stephen A Harrison. N Engl J Med 2021
357
5

Inflammation and metabolic disorders.
Gökhan S Hotamisligil. Nature 2006
4


The utility of radiological imaging in nonalcoholic fatty liver disease.
Sherif Saadeh, Zobair M Younossi, Erick M Remer, Terry Gramlich, Janus P Ong, Maja Hurley, Kevin D Mullen, James N Cooper, Michael J Sheridan. Gastroenterology 2002
4

Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man.
D R Matthews, J P Hosker, A S Rudenski, B A Naylor, D F Treacher, R C Turner. Diabetologia 1985
4

Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis.
Quentin M Anstee, Giovanni Targher, Christopher P Day. Nat Rev Gastroenterol Hepatol 2013
4

Preclinical Models for Studying NASH-Driven HCC: How Useful Are They?
Mark A Febbraio, Saskia Reibe, Shabnam Shalapour, Geraldine J Ooi, Matthew J Watt, Michael Karin. Cell Metab 2019
94
4

A lipidomic analysis of nonalcoholic fatty liver disease.
Puneet Puri, Rebecca A Baillie, Michelle M Wiest, Faridoddin Mirshahi, Jayanta Choudhury, Onpan Cheung, Carol Sargeant, Melissa J Contos, Arun J Sanyal. Hepatology 2007
851
4

Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity.
Jorge Henao-Mejia, Eran Elinav, Chengcheng Jin, Liming Hao, Wajahat Z Mehal, Till Strowig, Christoph A Thaiss, Andrew L Kau, Stephanie C Eisenbarth, Michael J Jurczak,[...]. Nature 2012
4

Lipotoxicity and the gut-liver axis in NASH pathogenesis.
Fabio Marra, Gianluca Svegliati-Baroni. J Hepatol 2018
357
4

Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease.
Jeong-Hoon Lee, Donghee Kim, Hwa Jung Kim, Chang-Hoon Lee, Jong In Yang, Won Kim, Yoon Jun Kim, Jung-Hwan Yoon, Sang-Heon Cho, Myung-Whun Sung,[...]. Dig Liver Dis 2010
566
4

Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease.
Paul Angulo, David E Kleiner, Sanne Dam-Larsen, Leon A Adams, Einar S Bjornsson, Phunchai Charatcharoenwitthaya, Peter R Mills, Jill C Keach, Heather D Lafferty, Alisha Stahler,[...]. Gastroenterology 2015
4

Non-invasive diagnosis of non-alcoholic steatohepatitis by combined serum biomarkers.
Jiayun Shen, Henry Lik-Yuen Chan, Grace Lai-Hung Wong, Paul Cheung-Lung Choi, Anthony Wing-Hung Chan, Hoi-Yun Chan, Angel Mei-Ling Chim, David Ka-Wai Yeung, Francis Ka-Leung Chan, Jean Woo,[...]. J Hepatol 2012
157
4

Pathogenesis of Nonalcoholic Steatohepatitis.
Mariana Verdelho Machado, Anna Mae Diehl. Gastroenterology 2016
233
4

Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease.
L Fedchuk, F Nascimbeni, R Pais, F Charlotte, C Housset, V Ratziu. Aliment Pharmacol Ther 2014
226
4

Fast gapped-read alignment with Bowtie 2.
Ben Langmead, Steven L Salzberg. Nat Methods 2012
4


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.